97 related articles for article (PubMed ID: 29525405)
1. Clinicopathological analysis of Large Cell Lung Carcinomas definitely diagnosed according to the New World Health Organization Criteria.
Bi Y; Qu Y; Liang Z; Liu Z; Zhang H; Liang X; Luo Y; Cao J; Zhang H; Feng R
Pathol Res Pract; 2018 Apr; 214(4):555-559. PubMed ID: 29525405
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary large cell carcinoma lacking squamous differentiation is clinicopathologically indistinguishable from solid-subtype adenocarcinoma.
Hwang DH; Szeto DP; Perry AS; Bruce JL; Sholl LM
Arch Pathol Lab Med; 2014 May; 138(5):626-35. PubMed ID: 23738762
[TBL] [Abstract][Full Text] [Related]
3. Next-Generation Sequencing of a Cohort of Pulmonary Large Cell Carcinomas Reclassified by World Health Organization 2015 Criteria.
Driver BR; Portier BP; Mody DR; Deavers M; Bernicker EH; Kim MP; Teh BS; Santacruz JF; Kopas L; Munden RF; Cagle PT
Arch Pathol Lab Med; 2016 Apr; 140(4):312-7. PubMed ID: 26430808
[TBL] [Abstract][Full Text] [Related]
4. [Clinicopathologic features and genetic profile of the redefined large cell lung carcinoma].
Hou LK; Zhang LP; Zhang W; Huang Y; Wu W; Dong ZW; Wu CY
Zhonghua Bing Li Xue Za Zhi; 2017 May; 46(5):298-302. PubMed ID: 28468033
[No Abstract] [Full Text] [Related]
5. KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy.
Guan JL; Zhong WZ; An SJ; Yang JJ; Su J; Chen ZH; Yan HH; Chen ZY; Huang ZM; Zhang XC; Nie Q; Wu YL
Ann Surg Oncol; 2013 Apr; 20(4):1381-8. PubMed ID: 23208128
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological characteristics and prognosis of patients with adenosquamous lung carcinoma.
Guo Y; Jia L; Shao GG; Sun HW; Wang XX; Wang GJ; Ma KW
J Huazhong Univ Sci Technolog Med Sci; 2015 Jun; 35(3):350-355. PubMed ID: 26072072
[TBL] [Abstract][Full Text] [Related]
7. The Landscape of Actionable Molecular Alterations in Immunomarker-Defined Large-Cell Carcinoma of the Lung.
Chan AW; Chau SL; Tong JH; Chow C; Kwan JSH; Chung LY; Lung RW; Tong CY; Tin EK; Law PP; Law WT; Ng CSH; Wan IYP; Mok TSK; To KF
J Thorac Oncol; 2019 Jul; 14(7):1213-1222. PubMed ID: 30978501
[TBL] [Abstract][Full Text] [Related]
8. Molecular spectrum of somatic EGFR and KRAS gene mutations in non small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel variations in Indian patients.
Das BR; Bhaumik S; Ahmad F; Mandsaurwala A; Satam H
Pathol Oncol Res; 2015 Jul; 21(3):675-87. PubMed ID: 25637496
[TBL] [Abstract][Full Text] [Related]
9. Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naïve Patients with Advanced Lung Adenocarcinoma.
Park J; Kobayashi Y; Urayama KY; Yamaura H; Yatabe Y; Hida T
PLoS One; 2016; 11(8):e0161081. PubMed ID: 27518729
[TBL] [Abstract][Full Text] [Related]
10. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
[TBL] [Abstract][Full Text] [Related]
11. Large cell carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and molecular biology.
Rossi G; Mengoli MC; Cavazza A; Nicoli D; Barbareschi M; Cantaloni C; Papotti M; Tironi A; Graziano P; Paci M; Stefani A; Migaldi M; Sartori G; Pelosi G
Virchows Arch; 2014 Jan; 464(1):61-8. PubMed ID: 24221342
[TBL] [Abstract][Full Text] [Related]
12. The new histologic classification of lung primary adenocarcinoma subtypes is a reliable prognostic marker and identifies tumors with different mutation status: the experience of a French cohort.
Mansuet-Lupo A; Bobbio A; Blons H; Becht E; Ouakrim H; Didelot A; Charpentier MC; Bain S; Marmey B; Bonjour P; Biton J; Cremer I; Dieu-Nosjean MC; Sautès-Fridman C; Régnard JF; Laurent-Puig P; Alifano M; Damotte D
Chest; 2014 Sep; 146(3):633-643. PubMed ID: 24676429
[TBL] [Abstract][Full Text] [Related]
13. [Driven Gene in Patients with Lung Squamous Cell Carcinoma:
Analysis of Clinicopathologic Characteristics and Prognosis].
Zhang T; Li J
Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):648-652. PubMed ID: 27760592
[TBL] [Abstract][Full Text] [Related]
14. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients.
Yoshizawa A; Sumiyoshi S; Sonobe M; Kobayashi M; Fujimoto M; Kawakami F; Tsuruyama T; Travis WD; Date H; Haga H
J Thorac Oncol; 2013 Jan; 8(1):52-61. PubMed ID: 23242438
[TBL] [Abstract][Full Text] [Related]
15. Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial.
Ready N; Jänne PA; Bogart J; Dipetrillo T; Garst J; Graziano S; Gu L; Wang X; Green MR; Vokes EE;
J Thorac Oncol; 2010 Sep; 5(9):1382-90. PubMed ID: 20686428
[TBL] [Abstract][Full Text] [Related]
16. [Large-cell lung carcinoma by the 2015 WHO classification: a clinicopathologic analysis of 93 cases].
Zhang JY; Xu XY; Shen Q; Wang YF; Wang X; Zhou XJ
Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):231-6. PubMed ID: 27033385
[TBL] [Abstract][Full Text] [Related]
17. Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.
Ulivi P; Chiadini E; Dazzi C; Dubini A; Costantini M; Medri L; Puccetti M; Capelli L; Calistri D; Verlicchi A; Gamboni A; Papi M; Mariotti M; De Luigi N; Scarpi E; Bravaccini S; Turolla GM; Amadori D; Crinò L; Delmonte A
Clin Lung Cancer; 2016 Sep; 17(5):384-390. PubMed ID: 26712101
[TBL] [Abstract][Full Text] [Related]
18. Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer.
Kaneda T; Yoshioka H; Tamiya M; Tamiya A; Hata A; Okada A; Niwa T; Shiroyama T; Kanazu M; Ishida T; Katakami N
BMC Cancer; 2018 Jan; 18(1):6. PubMed ID: 29291705
[TBL] [Abstract][Full Text] [Related]
19. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
20. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
